Navigation Links
Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
Date:5/14/2009

ify or obtain rights to new products; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2009 (File No. 001-34186). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 The Asian Automatic patient ... with analysis and forecast of revenue. The Automatic patient ... around $463.9 million by 2018, at a developing CAGR ... the TOC of the Asian Automatic patient billing market, ... This also provides a glimpse of the segmentation of ...
(Date:10/19/2014)... According to market research report “Outdoor Wi-Fi ... gateways)]- Global Advancements, Forecasts and Analysis (2013 - ... market with analysis and forecasting of the global ... drivers and the restrains for this market with ... , Browse 65 market data tables and 69 ...
(Date:10/18/2014)... 2014 The Asia-Pacific hardware encryption display ... Asia-Pacific with analysis and forecast of revenue. This market ... to reach $51,362.6 million by 2018, at a CAGR ... the TOC of the Asia-Pacific hardware encryption market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/18/2014)... October 18, 2014 The report ... Intelligence] - Text; Web; Speech; Machine; Video; Predictive ... Roadmap, Market Forecasts & Analysis (2013 - 2018) ... Market into various sub segments with an in-depth ... also identifies the factors driving this market, various ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 4The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5
... , EXTON, Pa., July 15 ... and Cancer Innovations, Inc. (CII), a privately held biotechnology company ... they have entered into an evaluation and option agreement in ... , , The ...
... , , MADISON, Wis., ... (CDI) today announced that it has exclusively in-licensed a US-issued patent portfolio ... cells (cardiomyocytes) in drug testing. , , ... and Indiana University-Purdue University Indianapolis (IUPUI), covers ...
... , PRINCETON, N.J., July 15 ... license agreement with Merck KGaA, Darmstadt, Germany, providing the global ... platform for the research, development and commercialization of their antibody ... , "We are extremely pleased about ...
Cached Biology Technology:Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 2Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 3Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing 2Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing 3BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA 2
(Date:10/17/2014)... This news release is available in German . ... need millions of sperms every day in order to reproduce? ... questions are the topic of the latest issue of the ... 16th, 2014). The evolutionary biologist Steven Ramm from Bielefeld University ... nature, it is not unusual for a female to copulate ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... - Animals that choose to eat in the presence of a ... go into a defensive mode and pay a physical penalty for ... crop pest hornworm caterpillar, a study shows. While other animals ... hornworm caterpillars slow or stop eating but actually keep up their ...
... to participate in ELIXIR ( www.elixir-europe.org ), a major ... in Europe. With one of Europe,s larger economies now ... is well placed to continue its excellent progress. ... infrastructure for managing biological data to support research and ...
... the IRCM, led by geneticist Dr. Jacques Drouin, recently ... inflammation. This important breakthrough will be published in tomorrow,s ... . IRCM scientists study glucocorticoids, a class ... reduce inflammation. They are used in medicine to treat ...
Cached Biology News:Caterpillar gets more from its food when predator is on the prowl 2Italy pledges to be part of ELIXIR research infrastructure 2Controlling inflammatory and immune responses 2
... monoclonal antibody reactive against the complex IV assembly ... in growing cultured cells. SURF1 is an important ... thought to participate in the folding of subunit ... Mutations of SURF1, particularly ones that result in ...
... (Thr183/Tyr185) Antibody Kit Kit Includes: ... #9251, 200 ul SAPK/JNK (56G8) Rabbit ... Cell Extracts, Catalog #9253, (4 Western ... #7074, 100 ul Anti-biotin IgG, HRP-linked ...
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Biology Products: